vct220
Peptideexperimental
Clinical trial activity
6 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
3
Phase 3
1
Phase 4
0
Earliest trial started Dec 27, 2023 (NCT06569355)
Timeline
Indications
Studied for
Mechanism of action
GLP1R agonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07056842 | Phase 1 | Jul 20, 2025 | Government of China |
| NCT07065058 | Phase 1 | Jul 1, 2025 | Government of China |
| NCT07011797 | Phase 2 | Jun 17, 2025 | Ji Xing Pharmaceuticals (Shanghai) Co., Ltd. |
| NCT06938529 | Phase 1 | Apr 18, 2025 | Government of China |
| NCT06939296 | Phase 3 | Dec 24, 2024 | Government of China |
| NCT06569355 | Phase 2 | Dec 27, 2023 | Government of China |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Government of China | Government | 5 | 5 | 3 | 2023 |
| Ji Xing Pharmaceuticals (Shanghai) Co., Ltd. | For profit | 1 | 1 | 1 | 2025 |
2 organizations
Page 1 / 1